Who are Telbivudine (Standard of Care)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Telbivudine, Lamivudine, Adefovir ,Enecavir, NAs+IFN-α, lamivudine or entecavir, entecavir, lamivudine, Telbivudine treatment, Lamivudine (LAM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/telbivudine-standard-of-care.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Telbivudine (Standard of Care) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Telbivudine (Standard of Care) (Telbivudine (Standard of Care)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Virology / Hepatology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Telbivudine (Standard of Care) (Telbivudine (Standard of Care)) — Nanfang Hospital, Southern Medical University. Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Telbivudine (Standard of Care) TARGET	Telbivudine (Standard of Care)	Nanfang Hospital, Southern Medical University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Telbivudine, Lamivudine, Adefovir ,Enecavir	Telbivudine, Lamivudine, Adefovir ,Enecavir	Shao-quan Zhang	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI)	Hepatitis B virus reverse transcriptase
NAs+IFN-α	NAs+IFN-α	Beijing 302 Hospital	marketed	Antiviral combination therapy	Hepatitis B virus reverse transcriptase; interferon-alpha receptor signaling
lamivudine or entecavir	lamivudine or entecavir	Sun Yat-sen University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI)	Hepatitis B virus reverse transcriptase; HIV reverse transcriptase
entecavir, lamivudine	entecavir, lamivudine	Asan Medical Center	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Telbivudine treatment	Telbivudine treatment	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Lamivudine (LAM)	Lamivudine (LAM)	Hoffmann-La Roche	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; Hepatitis B virus reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
ViiV Healthcare · 2 drugs in this class
Nanfang Hospital, Southern Medical University · 2 drugs in this class
Asan Medical Center · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Fu-Sheng Wang · 1 drug in this class
Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Telbivudine (Standard of Care) — Competitive Intelligence Brief. https://druglandscape.com/ci/telbivudine-standard-of-care. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab